Bioelectric medicines, also known as electroceuticals, are medical devices that are used to restore health in patients.  Bioelectric medicines function through neurostimulation and modulation of the nervous systems through electrical impulses. Global bioelectric medicine market will reach $39.06 billion by 2030, growing by 6.4% annually over 2020-2030 driven by growing geriatric population and rising acceptance of bioelectric medicines.

Highlighted with 71 tables and 76 figures, this 169-page report “Global Bioelectric Medicine Market 2020-2030 by Product Type (Implantable, Non-invasive), End User, and Region: Trend Forecast and Growth Opportunity” is based on a comprehensive research of the entire global bioelectric medicine market and all its sub-segments through extensively detailed classifications. Profound analysis and assessment are generated from premium primary and secondary information sources with inputs derived from industry professionals across the value chain. The report is based on studies on 2015-2019 and provides forecast from 2020 till 2030 with 2019 as the base year. (Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)

In-depth qualitative analyses include identification and investigation of the following aspects:

• Market Structure 

• Growth Drivers 

• Restraints and Challenges

• Emerging Product Trends & Market Opportunities

• Porter’s Fiver Forces

The trend and outlook of global market is forecast in optimistic, balanced, and conservative view by taking into account of COVID-19. The balanced (most likely) projection is used to quantify global bioelectric medicine market in every aspect of the classification from perspectives of Product Type, End User, and Region. 

Based on Product Type, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section.

Implantable Bioelectric Medicine

• Cardiac Pacemaker

• Implantable Cardioverter Defibrillators (ICD)

• Spinal Cord Stimulators (split into Chronic Pain, Failed Back Syndrome (FBSS), Ischemia by application)

• Cochlear Implants

• Deep Brain Stimulators (split into Parkinson’s Disease, Tremor, Depression, Other Deep Brain Stimulation Applications by application)

• Vagus Nerve Stimulators

• Sacral Nerve Stimulators (split into Urinary Incontinence and Fecal Incontinence by application)

• Retinal Implants

• Other Implantable Bioelectric Medicines

Non-invasive Bioelectric Medicine

• Transcutaneous Electrical Nerve Stimulators

• Transcranial Magnetic Stimulation (TMS)

• Pulsed Electromagnetic Field Therapy

• Other Non-invasive Bioelectric Medicines

Based on End User, the global market is segmented into the following sub-markets with annual revenue for 2019-2030 included in each section. 

• Hospitals and Clinics

• Research Institutes

• Individual Users

Geographically, the following regions together with the listed national/local markets are fully investigated:

• APAC (Japan, China, South Korea, Australia, India, and Rest of APAC; Rest of APAC is further segmented into Malaysia, Singapore, Indonesia, Thailand, New Zealand, Vietnam, and Sri Lanka)

• Europe (Germany, UK, France, Spain, Italy, Russia, Rest of Europe; Rest of Europe is further segmented into Belgium, Denmark, Austria, Norway, Sweden, The Netherlands, Poland, Czech Republic, Slovakia, Hungary, and Romania)

• North America (U.S., Canada, and Mexico)

• South America (Brazil, Chile, Argentina, Rest of South America)

• RoW (Saudi Arabia, UAE, South Africa)

For each aforementioned region and country, detailed analysis and data for annual revenue are available for 2019-2030. The breakdown of all regional markets by country and split of key national markets by Product Type and End User over the forecast years are also included.

The report also covers current competitive scenario and the predicted trend; and profiles key vendors including market leaders and important emerging players.

Specifically, potential risks associated with investing in global bioelectric medicine market are assayed quantitatively and qualitatively through GMD’s Risk Assessment System. According to the risk analysis and evaluation, Critical Success Factors (CSFs) are generated as a guidance to help investors & stockholders identify emerging opportunities, manage and minimize the risks, develop appropriate business models, and make wise strategies and decisions.

Key Players (this may not be a complete list and extra companies can be added upon request): 

Abbott Laboratories

BIOTRONIK SE & Co. KG

Boston Scientific Corporation

Cochlear Limited

electroCore, Inc.

Inspire Medical Systems, Inc.

LivaNova PLC

Medtronic PLC

NeuroMetrix, Inc

Nevro Corp.

Nuvectra Corporation

OMRON CORPORATION

Pixium Vision

Second Sight Medical Products Inc

SetPoint Medical

Sonova Holding AG

St. Jude Medical, Inc.

Stimwave LLC

(Please note: The report will be updated before delivery so that the latest historical year is the base year and the forecast covers at least 5 years over the base year.)